Webinar: Treatment of amyloidosis: Current opinions and future outlook
View our expert-led webinar where past, current, and future therapeutic strategies for amyloidosis are presented
Review a timeline of therapeutic strategies for transthyretin-related familial amyloid polyneuropathy (TTR-FAP), ranging from liver transplantation to antibody therapy
View the clinical trial data investigating the long-term efficacy and safety of therapeutic strategies in TTR-FAP and hereditary transthyretin amyloidosis (hATTR) with polyneuropathy
▼Tafamidis is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk for how to report side effects.
This is a recording of our live webinar. This webinar recording has been chapterized to enable ease of viewing.
Register now to unlock the content
Register now to access the content on this page
If not, register below
GL-hATTR-0205 | October 2021
Sign in or register to access exclusive content on this site